| Prev Close | 138.67 |
| Day Low/High | 138.33 / 140.19 |
| 52 Wk Low/High | 125.84 / 197.00 |
| Avg Volume | 2.81M |
Allergan Plc (AGN)
139.31
0.64
0.46
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 337.29M |
| Market Cap | 46.77B |
| EPS | -15.30 |
| P/E Ratio | N/A |
| Div & Yield | 2.96 (2.05%) |
Latest News
How Are My Ideas Working Out? January Trade Review (Part 2)
Clearly, the first half of the month shaped up better than the second half.
Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Allergan Could Retest Its December Low Before a Better Rally Attempt
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
Jim Cramer: What Are We to Make of Today's Market Decline?
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Try This Allergan Two-Week Setup
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
Allergan Must Prove Itself With Signs of More Aggressive Buying
A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.
Real Money Post Industrial Average Outperformed the Market in 2018
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
The Charts of Allergan Look Very Bearish With New Lows Made Yesterday
When I looked at the charts this morning I found a stock that could still decline further.
Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center
These are currently situations where companies are facing serious lawsuits.
Allergan Needs to Rebase on the Charts - Don't Rush It
Let's check the charts and technical indicators for some guidance.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Staying Long Apple Into Tuesday's Product Launch: Market Recon
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
A Bullish Options Play on Allergan
Buyout rumors aside, AGN is a name I still find attractive.
Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side
Let's check out the charts again so see how far this advance might carry.
Jim Cramer: This Is a Rotation, Not a Recession
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Biotechs: Adding to Radius Health, Flexion
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
Netflix and Twitter Are Among 29 Stocks Ready to Change Direction
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon
Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.
Big-Game Hunting for My Next 10-Bagger
It's every investor's dream to find a stock that goes up at least 1,000%; here are a few that did.
Is Goldman Sachs Going to Be the Next Allergan?
Don't count on it. The fundamentals paint two very different pictures, Cramer says.
Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't
You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.
Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday
As futures point higher, these are the headlines you need to get up to speed during your morning commute.
Jim Cramer: Tech Can't Do it All Alone
Tech and retail gains aren't enough to lead markets to new highs.
Passing on AGN
I took another quick analytical look at Allergan this weekend - for about 30 minutes. I continue to pass based on the absence of positive catalysts.
